Eliminating tuberculosis is possible. Yet, this preventable and largely treatable infectious disease takes the lives of 1.5 million people every year. The COVID-19 pandemic has jeopardized years of painstaking progress on eliminating the disease. The time for paradigm shift and a renewed focus on TB is now. In the run-up to the 2023 U.N. high level meeting on TB, join Devex and Stop TB Partnership in the #TalkingTB series.

Throughout this series, we’ll explore how to get efforts to end TB back on track — from hearing about the realities of living with the disease, to how technology could be leveraged to help, and what lessons can be learned from other diseases to tackle tuberculosis.

Themes

Dynamics of a disease: Characteristics and challenges

Dynamics of a disease: Characteristics and challenges

Read more
Living with TB: Community experiences and solutions

Living with TB: Community experiences and solutions

Read more
Leveraging technology: Scaling up tools for impact

Leveraging technology: Scaling up tools for impact

Coming soon

Gaining momentum: Looking forward, learning from past successes

Gaining momentum: Looking forward, learning from past successes

Coming soon

Stats

More news on TB

Global Fund pledge: ‘It’s not too late to take action,’ NGOs urge UK

Global Fund pledge: ‘It’s not too late to take action,’ NGOs urge UK


By Jenny Lei Ravelo

In two weeks, the board of the Global Fund to Fight AIDS, Tuberculosis and Malaria will be meeting to decide how much total grant funding will be made available to countries in the next three years, without additional pledges from big donors such as the U.K.

$250B plan to end TB seeks new vaccine by 2025

$250B plan to end TB seeks new vaccine by 2025


By Jenny Lei Ravelo

The plan requires $250 billion in funding from now through 2030 — a significant challenge for a disease that has been chronically underfunded.

Opinion: Why Canada needs to step up Global Fund support this year

Opinion: Why Canada needs to step up Global Fund support this year


By Leigh Raithby

The Global Fund has asked donors to increase their contributions by 30% over 2019 levels due to the devastating impact of COVID-19 on health services. Advocates around the world are looking to Canada to set this precedent.

New agreements cut price for short-course TB treatments to under $20

New agreements cut price for short-course TB treatments to under $20


By Jenny Lei Ravelo

Short-course rifapentine-based TB regimens help patients complete their preventive treatment, compared to taking multiple pills daily for six months. Health organizations hope the reduced pricing will lead more countries to roll out the shorter regimen.

What do you think about this series on TB?


#TalkingTB

#DevexSeries

TB Knowledge Hub

Produced by

Devex

Devex

Devex is the media platform for the global development community. A social enterprise, we connect and inform over one million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people.

In Partnership with

Stop TB Partnership

Stop TB Partnership

The Stop TB Partnership brings together expertise from a broad spectrum of country, regional, and global partners in our shared mission to revolutionize the TB space and end TB by 2030.